# Annexon, Inc.: overview ANNX · Nasdaq · CIK 1528115 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/annx.md) · [Financials](/companies/annx/financials.md) · [Filings](/companies/annx/filings.md) · [Insiders](/companies/annx/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.25)](/filings/0001193125-25-274240.md) | not reported | [(0.37)](/filings/0001193125-26-211931.md) | [(0.34)](/filings/0001193125-26-346779.md) | [(0.37)](/filings/0001193125-25-274240.md) | not reported | [(0.23)](/filings/0001193125-26-211931.md) | [(0.28)](/filings/0001193125-26-346779.md) | | Free cash flow | $m | not reported | [(36.0) d](/filings/0001193125-26-131782.md) | [(50.1)](/filings/0001193125-26-211931.md) | [(38.1) d](/filings/0001193125-26-346779.md) | [(52.4) d](/filings/0001193125-25-274240.md) | [(45.9) d](/filings/0001193125-26-131782.md) | [(46.8)](/filings/0001193125-26-211931.md) | [(48.1) d](/filings/0001193125-26-346779.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(3.40)](/filings/0000950170-23-006232.md) | [(2.60)](/filings/0000950170-24-036408.md) | [(1.77)](/filings/0000950170-25-030849.md) | [(1.01)](/filings/0001193125-26-131782.md) | [(1.34)](/filings/0001193125-26-131782.md) | | Free cash flow | $m | [(108)](/filings/0000950170-23-006232.md) | [(123)](/filings/0000950170-24-036408.md) | [(121)](/filings/0000950170-25-030849.md) | [(118)](/filings/0001193125-26-131782.md) | [(186)](/filings/0001193125-26-131782.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/annx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $111.5m | 19,518,496 | | Added +8,882,848 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $77.3m | 13,539,744 | | Added +2,601,235 | | [Redmile Group, LLC](/funds/1425738.md) | 2026-06-30 | $67.8m | 11,869,877 | | Reduced −2,679,891 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $56.1m | 9,824,321 | | Added +2,905,066 | | [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $49.7m | 8,698,173 | | Unchanged | | [Woodline Partners LP](/funds/1784547.md) | 2026-06-30 | $39.5m | 6,925,067 | | Added +4,587,930 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $39.2m | 6,871,015 | | Added +914,426 | | [MAK CAPITAL ONE LLC](/funds/1385702.md) | 2026-06-30 | $33.5m | 5,862,180 | | Added +1,138,137 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $33.3m | 5,825,579 | | Added +3,672,699 | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $25.5m | 4,458,646 | | Added +500,000 | ## Recent filings [All 511 filings](/companies/annx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-12 | 16:00 ET | [10-Q](/filings/0001193125-26-346779.md) | Quarterly report, period 2026-06-30 | 0001193125-26-346779 | | 2026-08-12 | 06:30 ET | [8-K](/filings/0001193125-26-345672.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-345672 | | 2026-08-10 | 16:35 ET | [8-K](/filings/0001193125-26-342524.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-342524 | | 2026-08-06 | 08:17 ET | [8-K](/filings/0001193125-26-336867.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-336867 | | 2026-07-30 | 16:25 ET | [8-K](/filings/0001193125-26-326199.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-326199 | | 2026-06-12 | 16:16 ET | [8-K](/filings/0001193125-26-269479.md) | 5.07 Shareholder vote results | 0001193125-26-269479 | | 2026-05-07 | 16:12 ET | [10-Q](/filings/0001193125-26-211931.md) | Quarterly report, period 2026-03-31 | 0001193125-26-211931 | | 2026-05-07 | 16:05 ET | [8-K](/filings/0001193125-26-211863.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-211863 | | 2026-04-27 | 16:06 ET | [DEF 14A](/filings/0001140361-26-017085.md) | Proxy statement, period 2026-06-11 | 0001140361-26-017085 | | 2026-03-30 | 17:30 ET | [10-K](/filings/0001193125-26-131782.md) | Annual report, period 2025-12-31 | 0001193125-26-131782 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-131782.md), filed Mar 30, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1528115 - Tickers: ANNX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.